182 related articles for article (PubMed ID: 35740552)
1. A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells.
Riillo C; Caracciolo D; Grillone K; Polerà N; Tuccillo FM; Bonelli P; Juli G; Ascrizzi S; Scionti F; Arbitrio M; Lopreiato M; Siciliano MA; Sestito S; Talarico G; Galea E; Galati MC; Pensabene L; Loprete G; Rossi M; Ballerini A; Gentile M; Britti D; Di Martino MT; Tagliaferri P; Tassone P
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740552
[TBL] [Abstract][Full Text] [Related]
2. UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.
Caracciolo D; Polerà N; Belmonte B; Conforti F; Signorelli S; Gulino A; Staropoli N; Tuccillo FM; Bonelli P; Juli G; Grillone K; Ascrizzi S; Cirillo M; Migale L; Ballerini A; Pelizon C; Di Martino MT; Tagliaferri P; Riillo C; Tassone P
Br J Haematol; 2024 Feb; 204(2):555-560. PubMed ID: 37963444
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
4. A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.
Riillo C; Polerà N; Di Martino MT; Juli G; Hokanson CA; Odineca T; Signorelli S; Grillone K; Ascrizzi S; Mancuso A; Staropoli N; Caparello B; Cerra M; Nisticò G; Tagliaferri P; Crea R; Caracciolo D; Tassone P
J Transl Med; 2023 May; 21(1):301. PubMed ID: 37143061
[TBL] [Abstract][Full Text] [Related]
5. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
6. The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.
Polerà N; Mancuso A; Riillo C; Caracciolo D; Signorelli S; Grillone K; Ascrizzi S; Hokanson CA; Conforti F; Staropoli N; Gervasi L; Di Martino MT; Arbitrio M; Nisticò G; Crea R; Tagliaferri P; Juli G; Tassone P
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980534
[TBL] [Abstract][Full Text] [Related]
7. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128
[TBL] [Abstract][Full Text] [Related]
8. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).
Heini AD; Bacher U; Pabst T
Br J Haematol; 2024 Feb; 204(2):389-390. PubMed ID: 37964473
[TBL] [Abstract][Full Text] [Related]
10. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
[TBL] [Abstract][Full Text] [Related]
11. Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.
Bechan GI; Lee DW; Zajonc DM; Heckel D; Xian R; Throsby M; van Meijer M; Germeraad WT; Kruisbeek AM; Egeler RM; Arceci RJ
Br J Haematol; 2012 Nov; 159(3):299-310. PubMed ID: 22934889
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors.
Belmontes B; Sawant DV; Zhong W; Tan H; Kaul A; Aeffner F; O'Brien SA; Chun M; Noubade R; Eng J; Ma H; Muenz M; Li P; Alba BM; Thomas M; Cook K; Wang X; DeVoss J; Egen JG; Nolan-Stevaux O
Sci Transl Med; 2021 Aug; 13(608):. PubMed ID: 34433637
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.
Chopra A; Bakhshi S; Pramanik SK; Pandey RM; Singh S; Gajendra S; Gogia A; Chandramohan J; Sharma A; Kumar L; Seth R; Rai S; Kumar R
Eur J Haematol; 2014 Mar; 92(3):211-8. PubMed ID: 24329989
[TBL] [Abstract][Full Text] [Related]
14. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
15. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
16. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
17. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
[TBL] [Abstract][Full Text] [Related]
18. A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.
de Weerdt I; Lameris R; Scheffer GL; Vree J; de Boer R; Stam AG; van de Ven R; Levin MD; Pals ST; Roovers RC; Parren PWHI; de Gruijl TD; Kater AP; van der Vliet HJ
Cancer Immunol Res; 2021 Jan; 9(1):50-61. PubMed ID: 33177109
[TBL] [Abstract][Full Text] [Related]
19. [CD19 antigen loss after treatment of Bispecific T-cell Engager and effective response to salvage bispecific CAR-T therapy in B cell acute lymphoblastic leukemia: a case report and literature review].
Fu XH; Wang Y; Wang HJ; Wei SN; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang JX; Wang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):282-286. PubMed ID: 32447930
[No Abstract] [Full Text] [Related]
20. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
